arrow
S

Saurabh Chhabra

Mayo Clinic College of Medicine and Science
H指数:46
被引数:8,659

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant

移植物抗宿主病预防措施塑造造血细胞移植后的T细胞生物学和免疫重建

2026-10-210
PRE
Coronary Artery Calcification as a Predictor of Survival in Patients Receiving Post-transplant Cyclophosphamide for GVHD Prophylaxis

冠状动脉钙化作为接受移植后环磷酰胺预防GVHD患者的生存预测因子

2026-09-012
OAAI
Prophylactic dexamethasone at the time of absolute lymphocyte expansion does not mitigate risk or event-free survival for immune effector cell associated delayed neurotoxicity

预防性地塞米松在绝对淋巴细胞扩增时并不能减轻与免疫效应细胞相关的迟发性神经毒性的风险或无事件生存期

2026-08-100
OA
Risk-Adjusted Comparison of Survival in Chronic Myelomonocytic Leukemia With and Without Allogeneic Stem Cell Transplant: Mayo Clinic Experience in 775 Consecutive Patients

慢性髓系单核细胞白血病患者行异基因干细胞移植与未移植者的风险调整生存比较:梅奥诊所775例连续患者的经验

2026-07-280
PRE
Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma

接受Ciltacabtagene-Autoleucel治疗的复发/难治性多发性骨髓瘤患者的早期治疗失败

2026-06-250
PRE
Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma

与贝antasine相比,氟达拉滨作为大细胞淋巴瘤CAR-T治疗前淋巴清除化疗的比较

2026-06-240
PREAI
Diagnosis and management of immune effector cell-associated enterocolitis (IEC-EC) following ciltacabtagene autoleucel

免疫效应细胞相关肠结肠炎(IEC-EC)的诊断与管理:基于cilta-cabtagene autoleucel的应用

2026-04-170
OAAI
Management of hematological toxicities after BCMA-directed CAR-T cell therapy

BCMA靶向CAR-T细胞疗法后的血液学毒性管理

2026-03-300
OAAI
Comparison of Patient-Reported Outcomes for Elranatamab in MagnetisMM-3 Versus Real-World Physician Choice of Therapy for Triple-Class Refractory Multiple Myeloma

Elranatamab在MagnetisMM-3研究中的患者报告结局与真实世界中医师选择的治疗方案在三类药物难治性多发性骨髓瘤中的比较

2026-03-210
OAAI
TIDRAKIZUMAB FOR THE PROPHYLAXIS OF GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

替达拉珠单抗在异基因造血干细胞移植后移植物抗宿主病的预防中的应用

2026-02-050
OAAI
Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma

免疫效应细胞相关迟发性神经毒性的临床病程、危险因素及缓解策略:ciltacabtagene autoleucel CAR-T在多发性骨髓瘤中的应用

2025-12-310
OAAI
AL Amyloidosis: A Real-World Experience with CAR-T Cell Therapy

AL淀粉样变性:CAR-T细胞疗法的真实世界经验

2025-10-170
OAAI
Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients

异基因干细胞移植在慢性髓单核细胞白血病中的应用:对138例梅奥诊所患者移植后生存及危险因素的分析

2025-10-060
OA
Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in new era: A CIBMTR study

异基因造血细胞移植在新时代晚期系统性肥大细胞增生症中的应用:一项CIBMTR研究

2025-09-220
PRE
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy

Dhakal, B.; Akhtar, O.S.; Fandrei, D.; Jensen, A.; Banerjee, R.; Pan, D.; Richard, S.; Friend, R.; Rees, M.J.; Costello, P.; 等. 多发性骨髓瘤的序贯靶向治疗:Talquetamab,一种GPRC5D双特异性抗体,作为BCMA CAR-T细胞疗法的桥梁。Blood 2025. [Google Scholar] [CrossRef]

Blood
IF23.1
2025-08-050
PRE
Donor Type Does Not Impact Late Graft Failure Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant CyclophosphamideBased Graft-Versus-Host Disease Prophylaxis

供体类型不影响低强度异基因造血细胞移植后的晚期移植失败,移植后基于环磷酰胺的移植物抗宿主病预防

2025-03-010
PRE
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma

雷帕霉素抵抗性多克隆Th1/Tc1细胞疗法(RAPA-201)安全地诱导复发、难治性多发性骨髓瘤的疾病缓解。

2025-01-280
OA